$25.32
Value $804M
COLL and MRK stock compared: price, dividend, valuation and results, from SEC filings.
$25.32
Value $804M
$147.76
Value $365B
Collegium Pharmaceutical (COLL) has a market value of $804M and Merck & Company (MRK) $365B. Over the last year, with dividends, COLL moved -46.5% and MRK +66.3%. The P/E is 21.1 for COLL and 148.9 for MRK. Dividend yield: COLL none, MRK 2.30%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
COLL$804M
MRK$365B
MRK is 454 times COLL
Revenue, 12 months
COLL$815M
MRK$67.4B
MRK is 83 times COLL
Net income, 12 months
COLL$38M
MRK$2.5B
MRK is 64 times COLL
Operating margin
COLL15.2%
MRK–
ROIC
COLL19.2%
MRK3.9%
15.3 points apart
P/E
COLL21.1
MRK148.9
MRK is 7.1 times COLL
Dividend yield
COLL0.0%
MRK2.3%
2.3 points apart
5-year return
COLL+30.0%
MRK+104.9%
74.9 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
COLL+30.0%
MRK+104.9%
| Period | COLLWith dividends | MRKWith dividends |
|---|---|---|
| 1 year since November 12, 2025 | -46.5%Price -46.5% | +66.3%Price +61.6% |
| 3 years since November 13, 2023 | +0.5%+0.2% a yearPrice +0.5% | +58.0%+16.5% a yearPrice +44.2% |
| 5 years since November 12, 2021 | +30.0%+5.4% a yearPrice +30.0% | +104.9%+15.4% a yearPrice +75.9% |
| 10 years since November 15, 2016 | +53.3%+4.4% a yearPrice +53.3% | +230.1%+12.7% a yearPrice +143.3% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
COLLCollegium PharmaceuticalMRKMerck & Company
| Price | $25.32 | $147.76 |
|---|---|---|
| Market value | $804M | $365B |
| Enterprise value (EV) | – | $409B |
| P/E | 21.1 | 148.9 |
| P/E, 5-year median | 19.6 | 14.8 |
| P/B | 2.7 | 8.1 |
| EV/EBIT | – | 86.0 |
| Free cash flow yield | 41.8% | 4.0% |
| Revenue, 12 months | $815M | $67.4B |
|---|---|---|
| Net income, 12 months | $38M | $2.5B |
| Free cash flow, 12 months | $336M | $14.7B |
| Earnings per share, 12 months | $1.20 | $0.98 |
| Revenue growth, year on year | 23.6% | 1.3% |
| Revenue growth a year, past | +20.3%over 5 years | +9.4%over 5 years |
| EPS growth a year, past | +17.9%over 5 years | +21.2%over 5 years |
| Gross margin | 59.1% | 71.8% |
|---|---|---|
| Operating margin | 15.2% | – |
| Net margin | 4.7% | 3.6% |
| ROIC | 19.2% | 3.9% |
| ROE | 12.8% | 5.2% |
| Cash | $145M | $9.7B |
|---|---|---|
| Total debt | – | $53.8B |
| Net debt / EBITDA | – | 5.7 |
| Interest cover | 1.6× | 2.4× |
| Dividend yield | – | 2.3% |
|---|---|---|
| Dividend per share, 12 months | – | $3.40 |
| Dividend growth a year, past | – | +5.8%over 5 years |
| Buyback yield | 3.1% | 1.4% |
| Shareholder yield | 3.1% | 3.7% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Merck & Company ($365B) is about 454.4 times Collegium Pharmaceutical ($804M), at today's prices.
Since November 15, 2016, COLL's price moved +53.3% and MRK's +143.3%. With dividends: COLL +53.3% (+4.4% a year), MRK +230.1% (+12.7% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Collegium Pharmaceutical and 2.30% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.
At today's price, the P/E is 21.1 for COLL and 148.9 for MRK. The median of the last five years was 19.6 and 14.8, which shows where each stands against its own past.
Over the last twelve months, the net margin was 4.7% for Collegium Pharmaceutical and 3.6% for Merck & Company, and the operating margin 15.2% and –. Revenue was $815M and $67.4B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.